BCYC
Bicycle Therapeutics plc
15.99
USD
This page is just a preview of the data found in TrendSpider’s full version
Bicycle Therapeutics plc stock is up 20.32% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 26 Oct 15:19 | 19 Jan, 2024 | 17.50 | 27 | ||
| 26 Oct 15:20 | 19 Jan, 2024 | 17.50 | 27 | ||
| 02 Nov 15:17 | 15 Dec, 2023 | 17.50 | 84 | ||
| 02 Nov 16:12 | 19 Jan, 2024 | 17.50 | 300 | ||
| 03 Nov 14:53 | 15 Dec, 2023 | 30.00 | 398 | ||
| 03 Nov 14:53 | 15 Dec, 2023 | 30.00 | 398 | ||
| 03 Nov 14:56 | 15 Dec, 2023 | 30.00 | 398 | ||
| 16 Nov 17:33 | 15 Dec, 2023 | 15.00 | 1001 | ||
| 17 Nov 18:07 | 15 Dec, 2023 | 12.50 | 36 | ||
| 27 Nov 15:47 | 15 Dec, 2023 | 15.00 | 1175 |
Bicycle Therapeutics plc develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema. BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT
